直接抗病毒药物时代下对丙型肝炎研究的挑战

直接抗病毒药物时代下对丙型肝炎研究的挑战

Hepatitis C virus (HCV) is an important human pathogen that causes chronic viral hepatitis worldwide. HCV infection, often persistent and asymptomatic, could lead to liver fibrosis/cirrhosis and hepatocellular carcinoma. The interferon/ribavirin therapy has been widely used for treating chronic hepa...

Full description

Bibliographic Details
Main Author: ZHONG Jin
Format: Article
Language:zho
Published: Editorial Department of Journal of Clinical Hepatology 2014-06-01
Series:Linchuang Gandanbing Zazhi
Subjects:
hepatitis C; direct antiviral agents; review
Online Access:http://www.lcgdbzz.org/qk_content.asp?id=5805&ClassID=4241494
id doaj-c8625d1bd1ad4515ba7c34a410c83212
record_format Article
spelling doaj-c8625d1bd1ad4515ba7c34a410c832122020-11-24T23:38:45ZzhoEditorial Department of Journal of Clinical HepatologyLinchuang Gandanbing Zazhi1001-52561001-52562014-06-0130648148410.3969/j.issn.1001-5256.2014.06.001直接抗病毒药物时代下对丙型肝炎研究的挑战 ZHONG Jin0Institute Pasteur of Shanghai, Chinese Academy of SciencesHepatitis C virus (HCV) is an important human pathogen that causes chronic viral hepatitis worldwide. HCV infection, often persistent and asymptomatic, could lead to liver fibrosis/cirrhosis and hepatocellular carcinoma. The interferon/ribavirin therapy has been widely used for treating chronic hepatitis C, but it is not always effective and has strong side effects. The development of small-molecule direct antiviral agents (DAAs) has greatly improved the curing efficiency of chronic hepatitis C therapeutics and will likely replace the interferon-based therapy in the future. However, these developments do not necessarily suggest that the problems of chronic hepatitis C have been completely solved. The HCV research is still facing many challenges in this new DAA era.http://www.lcgdbzz.org/qk_content.asp?id=5805&ClassID=4241494hepatitis C; direct antiviral agents; review
collection DOAJ
language zho
format Article
sources DOAJ
author ZHONG Jin
spellingShingle ZHONG Jin
直接抗病毒药物时代下对丙型肝炎研究的挑战
Linchuang Gandanbing Zazhi
hepatitis C; direct antiviral agents; review
author_facet ZHONG Jin
author_sort ZHONG Jin
title 直接抗病毒药物时代下对丙型肝炎研究的挑战
title_short 直接抗病毒药物时代下对丙型肝炎研究的挑战
title_full 直接抗病毒药物时代下对丙型肝炎研究的挑战
title_fullStr 直接抗病毒药物时代下对丙型肝炎研究的挑战
title_full_unstemmed 直接抗病毒药物时代下对丙型肝炎研究的挑战
title_sort 直接抗病毒药物时代下对丙型肝炎研究的挑战
publisher Editorial Department of Journal of Clinical Hepatology
series Linchuang Gandanbing Zazhi
issn 1001-5256
1001-5256
publishDate 2014-06-01
description Hepatitis C virus (HCV) is an important human pathogen that causes chronic viral hepatitis worldwide. HCV infection, often persistent and asymptomatic, could lead to liver fibrosis/cirrhosis and hepatocellular carcinoma. The interferon/ribavirin therapy has been widely used for treating chronic hepatitis C, but it is not always effective and has strong side effects. The development of small-molecule direct antiviral agents (DAAs) has greatly improved the curing efficiency of chronic hepatitis C therapeutics and will likely replace the interferon-based therapy in the future. However, these developments do not necessarily suggest that the problems of chronic hepatitis C have been completely solved. The HCV research is still facing many challenges in this new DAA era.
topic hepatitis C; direct antiviral agents; review
url http://www.lcgdbzz.org/qk_content.asp?id=5805&ClassID=4241494
work_keys_str_mv AT zhongjin zhíjiēkàngbìngdúyàowùshídàixiàduìbǐngxínggānyányánjiūdetiāozhàn
_version_ 1725515977028796416

Similar Items